CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 132 enrolled
Drug / intervention
TachoSil +1 moredrug
Likely dose
Not stated in record
Key inclusion· 4
  • Scheduled for elective open liver surgery
  • Age ≥22 years at enrollment
  • Intraoperatively: target bleeding site at liver resection plane where conventional hemostasis (suture, ligature, cautery) is ineffective or impractical, requiring hemostatic agent
  • Target bleeding site severity SBSS score 1, 2, or 3 (minimal, mild, or moderate)
Key exclusion· 16
  • Target bleeding site from large arterial or venous defect requiring vascular reconstruction with vessel patency maintenance
  • Planned surgery on organs other than liver, biliary, or vascular system
  • Planned staged liver surgery (e.g., ALPPS)
  • Multiple antithrombotic therapies at therapeutic dosage up to surgery (aspirin monotherapy allowed)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05385952
NCT05385952N/ACompleted

A Prospective, Multicenter, Randomized Clinical Investigation Evaluating the Safety and Efficacy of GATT-Patch Versus TachoSil for Hemostasis During Open Liver Surgery

GATT Technologies BV·interventional·Posted May 23, 2022·Updated Mar 4, 2026

In Brief

A clinical study evaluating GATT-Patch (currently named ETHIZIA) and TachoSil for Intraoperative Bleeding and 2 related conditions. Completed, enrolled 132 participants across 10 sites in 3 countries.

Detailed Summary

This is a pre-market, prospective, randomized (2:1), multicenter, multi-national pivotal clinical investigation. The purpose of this investigation is to determine the clinical safety and performance of GATT-Patch as compared with TachoSil for the management of minimal, mild, or moderate bleeding during elective open liver surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Netherlands, United States
CollaboratorsSyneos Health

Timeline

N/ACompletedFinished
2023202420252026
First PostedMay 23, 2022
Enrollment StartAug 4, 2022
Primary CompletionMay 10, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.1 years ago

Interventions

GATT-Patch (currently named ETHIZIA)device

GATT-Patch (currently named ETHIZIA) is a sterile, flexible and resorbable hemostatic sealing patch. It presents as a blue, soft, flexible, porcine gelatin fiber-based carrier impregnated with an NHS-POx / NU-POx granulate. GATT-Patch measures 10 cm long by 5 cm wide. GATT-Patch is active and can be applied on both sides. Blue color is an aid to visualize GATT-Patch when applied onto a bleeding location. GATT-Patch is indicated for use as an adjunct to hemostasis in surgery for minimal, mild or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. GATT-Patch is intended to be used for management of hemorrhage during surgeries on the liver.

TachoSildrug

TachoSil is a topical fibrin sealant patch consisting of human fibrinogen and human thrombin coated onto an equine collagen sponge. TachoSil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery, when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.